Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a
Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a technetium-labeled agent. DuPont Merck, of North Billerica, MA, plans to begin shipping Neurolitein January. The product is indicated for brain perfusion studiesin stroke patients (SCAN 9/14/94).
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.